News

PierianDx, the leading genomics technology company that enables precision medicine, announced today a full range of expanded services to support adoption of the company’s enterprise software platform, the Clinical Genomics WorkSpace (CGW).

“Since PierianDx was first founded in 2014, our mission has always been to enable precision medicine for our customers,” said PierianDx founder and CEO Rakesh Nagarajan. “CGW’s end-to-end workflow and robust knowledgebase has been the backbone of that promise, and now our expanded Clinical Genomics Services doubles down on that mission.”

The other component of PierianDx’s technology-enabled scientific and medical services is focused on the clinical lab, which includes services for assay validation, assay selection, and interpretation. PierianDx also offers turnkey and custom assays through its lab services, which is performed in a laboratory that has been accredited by the College of American Pathologists (CAP) and/or has Clinical Laboratory Improvement Amendments (CLIA) certification.

PierianDx’s Clinical Genomics Services team is comprised of more than 40 medical professionals, scientists, and bioinformatics experts delivering services across the spectrum of the molecular pathology lab workflow.

Nagarajan said the services expansion is part of PierianDx’s solution approach that recognizes customers have varying needs for accelerating their precision medicine programs.

“Most customers have their own in-house capabilities and simply need a trusted partner to ramp up their efforts,” Nagarajan explained. “CGW, our robust knowledgebase of shared interpretations, and our support services align seamlessly with a clinical lab’s workflow, transforming our technology platform into a true solution for our customers.”